Bio-Rad Laboratories (BIO) 145.40 $BIO
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 31.12 (+0.82), INSY: 18.05 (+2.85), CSII: 19.85 (+0.47), BIO: 145.40 (-0.65), CNAT: 2.39 (+0.06)
Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016
Marketwire Canada - Mon Jul 11, 1:03PM CDT
HERCULES, CA--(Marketwired - Jul 11, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2016 on Wednesday, August 3, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 145.40 (-0.65)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), BIO.B: 146.00 (-1.50)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 10.44 (+0.07), BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), EXAC: 27.12 (-0.14)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 159.93 (-0.65), BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing
Zacks Equity Research - Zacks Investment Research - Mon Dec 21, 1:25PM CST
Bio-Rad's (BIO) D-100 System delivers rapid high-quality HbA1c testing, without sacrificing the ability to detect hemoglobin variants that can interfere with the interpretation of test results.
CAPR: 3.79 (+0.04), ICUI: 115.70 (-0.32), INSY: 18.05 (+2.85), BIO: 145.40 (-0.65)
10X Genomics Founders Prevail in Dispute with Bio-Rad
BusinessWire - Mon Dec 21, 6:00AM CST
10X Genomics, Inc., today announced that its founders and executive officers, Drs. Serge Saxonov, Benjamin Hindson and Kevin Ness, have unequivocally prevailed in an arbitrated dispute brought against them by Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 31.12 (+0.82), INSY: 18.05 (+2.85), CSII: 19.85 (+0.47), BIO: 145.40 (-0.65), CNAT: 2.39 (+0.06)
Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016
Marketwire Canada - Mon Jul 11, 1:03PM CDT
HERCULES, CA--(Marketwired - Jul 11, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2016 on Wednesday, August 3, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day. BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA). BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 145.40 (-0.65)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO.
on Thursday reported first-quarter profit of $12.3 million. BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016. BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), BIO.B: 146.00 (-1.50)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year. BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 10.44 (+0.07), BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), EXAC: 27.12 (-0.14)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety. IBM: 159.93 (-0.65), BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators." BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors. BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)
FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing
Zacks Equity Research - Zacks Investment Research - Mon Dec 21, 1:25PM CST
Bio-Rad's (BIO) D-100 System delivers rapid high-quality HbA1c testing, without sacrificing the ability to detect hemoglobin variants that can interfere with the interpretation of test results.
CAPR: 3.79 (+0.04), ICUI: 115.70 (-0.32), INSY: 18.05 (+2.85), BIO: 145.40 (-0.65)
10X Genomics Founders Prevail in Dispute with Bio-Rad
BusinessWire - Mon Dec 21, 6:00AM CST
10X Genomics, Inc., today announced that its founders and executive officers, Drs. Serge Saxonov, Benjamin Hindson and Kevin Ness, have unequivocally prevailed in an arbitrated dispute brought against them by Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)
